Pacific Biosciences of California Inc

Pacific Biosciences of California Inc Stock Forecast & Price Prediction

Live Pacific Biosciences of California Inc Stock (PACB) Price
$5.74

5

Ratings

  • Buy 3
  • Hold 2
  • Sell 0
Disclaimer : The analyst ratings and price forecast data are provided by Tradefeeds. The data is sourced from Wall Street analysts and other experienced experts. The figures presented are solely a forecast and not a guarantee of future price performance. The information presented is not a recommendation to buy or sell the stock.

Stock Price

$5.74

P/E Ratio

P/E Ratio not available for PACB

Volume Traded Today

$18.1M

Dividend

Dividends not available for PACB

52 Week High/low

14.55/5.68

Pacific Biosciences of California Inc Market Cap

$1.54B

🛑 Alert: These ten stocks could have higher potential than $PACB 🛑

Before you buy PACB you’ll want to see this list of ten stocks that have huge potential. Want to see if PACB made the cut? Enter your email below

PACB Summary

From what 5 stock analysts predict, the share price for Pacific Biosciences of California Inc (PACB) might increase by 84.67% in the next year. This is based on a 12-month average estimation for PACB. Price targets go from $8.00 to $14.00. The majority of stock analysts believe PACB is a buy. Please note analyst price targets are not guaranteed and could be missed completely.

PACB Analyst Ratings

About 5 Wall Street analysts have assignedPACB 3 buy ratings, 2 hold ratings, and 0 sell ratings. This means that analysts expect Pacific Biosciences of California Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on PACB. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.

PACB stock forecast by analyst

Analyst/Firm

Rating

Price Target

Change

Date

david westenberg
Piper Sandler

Hold

$8.0

rated

Feb 16, 2024
john sourbeer
UBS

Buy

$12.0

maintained

Feb 16, 2024
kyle mikson cfa
Canaccord Genuity

Buy

$14.0

maintained

Feb 16, 2024
ross osborn
Cantor Fitzgerald

Buy

$9.0

maintained

Feb 16, 2024
luke sergott
Barclays

Hold

$8.0

maintained

Jan 25, 2024
mason carrico
Stephens

Buy

$11.0

rated

Dec 13, 2023
doug schenkel
Wolfe Research

Hold

None

initiatedcoverage

Dec 12, 2023
daniel brennan
TD Cowen

Buy

$19.0

maintained

Nov 6, 2023
sung ji nam
Scotiabank

Buy

$15.0

reiterated

Nov 1, 2023
tejas savant
Morgan Stanley

Hold

$10.0

maintained

Oct 24, 2023
matthew sykes
Goldman Sachs

Buy

$11.0

maintained

Oct 17, 2023
eve burstein
Bernstein

Buy

$11.0

initiatedcoverage

Sep 28, 2023
rachel vatnsdal
J.P. Morgan

Buy

$16.0

maintained

Aug 3, 2023
jack meehan
Nephron

Buy

$16.0

initiatedcoverage

May 16, 2023
julia qin
J.P. Morgan

Buy

$13.0

maintained

Nov 17, 2022
gary tenner
D.A. Davidson

Hold

$25.0

maintained

Oct 24, 2022
tycho peterson
J.P. Morgan

Buy

$30.0

maintained

Feb 16, 2022
steven mah
Cowen & Co.

Buy

$52.0

upgraded

Feb 11, 2021
craig bijou
Bank of America Securities

Buy

$5.0

initiatedcoverage

Mar 9, 2020
jordan abrams
Cantor Fitzgerald

Hold

$8.0

maintained

Jun 20, 2019

PACB Company Information

Pacific Biosciences of California, Inc. designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides sequencing systems; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases. It also offers binding kits, such as modified DNA polymerase used to bind SMRTbell libraries to the polymerase in preparation for sequencing; and sequencing kits comprise reagents required for on-instrument, real-time sequencing, including the phospholinked nucleotides. The company serves research institutions; commercial laboratories; genome centers; public health labs, hospitals and clinical research institutes, contract research organizations, and academic institutions; pharmaceutical companies; and agricultural companies. It markets its products through a direct sales force in North America and Europe, as well as through distribution partners in Asia, Europe, the Middle East, Africa, and Latin America. It has a development and commercialization agreement with Invitae Corporation; and a collaboration with Radboud University Medical to explore genetic causes of rare and genetic diseases. The company was formerly known as Nanofluidics, Inc. and changed its name to Pacific Biosciences of California, Inc. in 2005. Pacific Biosciences of California, Inc. was incorporated in 2000 and is headquartered in Menlo Park, California.

PACB
Pacific Biosciences of California Inc (PACB)

When did it IPO

2010

Staff Count

769

Country

United States

Sector/Industry

Healthcare/Medical Devices

CEO

Mr. Christian O. Henry M.B.A.

Market Cap

$1.54B

Pacific Biosciences of California Inc(PACB) Financial Data

In 2023, PACB generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that PACB's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.

Revenue From 2019

N/A

Revenue From 2020

N/A

0.00 %
From Previous Year

Revenue From 2021

N/A

0.00 %
From Previous Year

Revenue From 2022

N/A

0.00 %
From Previous Year
  • Revenue TTM $200.5M
  • Operating Margin TTM -1.42%
  • Gross profit TTM $49.0M
  • Return on assets TTM -0.11%
  • Return on equity TTM -0.49%
  • Profit margin -1.5296899%
  • Book value 2.63%
  • Market capitalisation $1.54B
  • Revenue for 2020 N/A
  • Revenue for 2021 N/A
  • Revenue for 2022 N/A
  • EPS this year -1.21
  • EPS next year N/A

Pacific Biosciences of California Inc(PACB) Latest News

... ...

Similar Stocks to Pacific Biosciences of California Inc PACB

🛑 Alert: These ten stocks could have higher potential than $PACB 🛑

Before you buy PACB you’ll want to see this list of ten stocks that have huge potential. Want to see if PACB made the cut? Enter your email below

...

PACB Frequently asked questions

The highest forecasted price for PACB is $14.00 from kyle mikson cfa at Canaccord Genuity.

The lowest forecasted price for PACB is $8.00 from drew jones from Stephens

The PACB analyst ratings consensus are 3 buy ratings, 2 hold ratings, and 0 sell ratings.